3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Glioma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Cyclophosphamide
12
fludarabine
11
fludarabine phosphate
8
Tacrolimus
8
Melphalan
8
Whole-Body Irradiation
7
Mycophenolic Acid
7
Thiotepa
6
Imatinib Mesylate
6
nilotinib
5
Granulocyte Colony-Stimulating Factor
5
Dasatinib
5
Busulfan
5
venetoclax
4
ponatinib
4
asciminib
4
Mesna
4
bosutinib
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
thymoglobulin
2
ruxolitinib
2
blinatumomab
2
Patient Reported Outcome Measures
2
Filgrastim
2
Antilymphocyte Serum
2
selinexor
1
plerixafor
1
Triamcinolone
1
Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
BID protein, human
×
Clear all
NCT03906292
2025-03-10
CMLXI
University of Jena
Phase 2
Active not recruiting
125 enrolled